Introduction {#s1}
============

PAK1 is a major downstream effector of the Rho-GTPases Cdc42 and Rac, which act as molecular switches that transduce various extracellular signals into intracellular responses [@pone.0071495-Manser1]. PAK1, the best-characterized member of the PAK family, forms a *trans*-inhibited dimer in its inactive state, in which the catalytic domain of one PAK1 monomer is blocked by the autoinhibitory domain (AID) of the other [@pone.0071495-Lei1], [@pone.0071495-Parrini1]. This autoinhibitory conformation is disrupted by binding of the GTP-bound Cdc42 and Rac to the CRIB (Cdc42/Rac-interactive binding region) domain [@pone.0071495-Morreale1], [@pone.0071495-Tu1], [@pone.0071495-Buchwald1], leading to autophosphorylation at specific sites including T423 within the activation loop and consequent activation of PAK1 [@pone.0071495-Sahyoun1], [@pone.0071495-Chong1]. Efficient activation of PAK1 requires its membrane targeting. PAK1 is recruited to the plasma membrane via the SH3-containing proteins Nck and Grb2 [@pone.0071495-Bokoch1], [@pone.0071495-Lu1], [@pone.0071495-Daniels1], where it may be activated by signaling molecules such as PDK1 kinase [@pone.0071495-King1], sphingosine [@pone.0071495-Bokoch2], [@pone.0071495-Zenke1] and PIP2 [@pone.0071495-Kapoor1] in a manner independent of the GTPases.

PAK1 is frequently overexpressed and hyperactivated by dysregulation of a number of signaling pathways in human cancer cells that are stimulated by growth factor receptors such as EGFR, PDGFR, and VEGFR [@pone.0071495-Kumar1]. The activated PAK1 in turn promotes cancer cell invasion and metastasis by phosphorylating key regulators involved in cytoskeleton reorganization, such as Lim kinase (LIMK) [@pone.0071495-Thullberg1], [@pone.0071495-Wang1] and the P41-ARC subunit of the ARP2/3 [@pone.0071495-Yoshioka1]. PAK1 activation also stimulates anti-apoptotic pathways, such as the Pak-Raf1-Bad [@pone.0071495-Dadke1], [@pone.0071495-Cotteret1] and NFκB [@pone.0071495-Dadke1] pathways, rendering PAK1 attractive as a cancer therapeutic target [@pone.0071495-Lee1]. There has been a rapid expansion in the development of peptides as potential drugs for cancer therapy over the last decade [@pone.0071495-BellmannSickert1]. HIV-1 TAT protein transduction domain-mediated delivery of macromolecules has emerged as an alternative approach for the internalization of proteins into the cell from the external environment [@pone.0071495-Snyder1]. PAK peptides have been also examined by two groups in different methods; 1) treatment of the PAK peptide (aa 11--23) that interacts with NCK [@pone.0071495-Kiosses1]; 2) expression of PAK1 inhibitory domain (aa 83--149) [@pone.0071495-Balasenthil1].

The crystal structure of the Cdc42-PAK1 complex revealed that the CRIB domain of PAK interacts with Cdc42 by forming an intermolecular β-sheet between residues Y40-I46 of Cdc42 and I76-H83 of PAK but that this interaction seems to be disrupted by the presence of a β-bulge in PAK formed by the sequence ~79~SDF~81~ [@pone.0071495-Morreale1]. To get insights into the role of this sequence, here we investigated the effect of the mutation at S79, one of the three residues of the ~79~SDF~81~ sequence on the regulation of PAK1 activity. Our biochemical and cell biological studies have demonstrated that S79 plays a crucial role in the PAK1 interaction with Cdc42 and Rac1 and is required for PAK1-mediated malignant transformation of prostate epithelial cells. Thus, this study uncovers a previously unappreciated role of S79 in the regulation of PAK1 activity and demonstrates a novel concept for the activation of PAK1 by the GTPases.

Results and Discussion {#s2}
======================

PAK1^S79^ Plays an Important Role in Autophosphorylation and Kinase Activities of PAK1 {#s2a}
--------------------------------------------------------------------------------------

PAK1 interacts with Cdc42 and Rac via the CRIB domain (amino acid residues 74-88) [@pone.0071495-Manser1]. A study indicated that ~79~SDF~81~ motif is positioned near the center of the CRIB domain and appears to disrupt the intermolecular β-sheet interaction between residues Y40-I46 of Cdc42 (blue) of Cdc42 and I76-H83 of PAK (red) [@pone.0071495-Morreale1] ([Fig. 1A](#pone-0071495-g001){ref-type="fig"}). Our sequence alignment showed that this motif is conserved only in higher eukaryotic organisms, suggesting diverse mechanisms for the regulation of PAK1 activity ([Fig. 1B](#pone-0071495-g001){ref-type="fig"}). Increased PAK1 activity is associated with autophosphorylation at specific sites, including S144, S199 and T423 [@pone.0071495-Zenke1]. To address whether S79 of PAK1 (PAK1^S79^) is required for autophosphorylation and kinase activity of PAK1, we assessed phosphorylation states of these residues in PAK1 (WT) and PAK1^S79A^ by IP/Western blot analysis and PAK1 kinase activity by in vitro kinase assay, respectively. Our results show that S79A mutation significantly decreases the phosphorylation of the three residues ([Fig. 1C](#pone-0071495-g001){ref-type="fig"}) and kinase activity of PAK1 toward the PAK1 substrates MBP (myelin basic protein) and DLC1 (dynein light chain 1) peptide ([Fig. 1D](#pone-0071495-g001){ref-type="fig"}). PAK1 activation is stimulated by a variety of factors including epidermal growth factor (EGF) [@pone.0071495-Kumar1]. We found that S79A mutation markedly decreases EGF-induced PAK1 autophosphorylation at both S144 and T423 ([Fig. 1E](#pone-0071495-g001){ref-type="fig"}).

![S79 within the CRIB domain is crucial for autophosphorylation and kinase activity of PAK1.\
Overall Structures of CRIP domain of PAK1 and Sequence Comparisons. (**A**) Ribbon diagram showing a structural overview of CRIP domain of PAK1 (red) with bound Cdc42 (blue). Data Bank ID number 1E0A and visualized using Molsoft ICM Browser (Molsoft, L.L.C., San Diego, CA, USA). (**B**) Multiple sequence alignment of the amino acid sequence of PAK1 from 17 species. (**C**) Western blot analysis of phosphorylation of T423, S199, and S144 and of GFP-PAK1^WT^ or GFP-PAK1^S79A^. (**D**) The kinase activity of PAK1 (GFP-PAK1^WT^ or GFP-PAK1^S79A^) was assessed by *in vitro* phosphorylation assay using MBP (upper) or DLC1 peptide (lower) as substrate. (**E**) Western blot analysis of the effect of S79A mutation on the PAK1 autophosphorylation using anti-T423 and anti-S144 phospho-specific PAK1 antibodies. Cells were unstimulated (−) or stimulated (+) by EGF (100 ng/ml).](pone.0071495.g001){#pone-0071495-g001}

PAK1^S79^ is Required for the Interaction of PAK1 with Rac1 {#s2b}
-----------------------------------------------------------

Given that PAK1 activation is induced by the binding of the activated GTPase to the CRIB domain [@pone.0071495-Morreale1], [@pone.0071495-Tu1], [@pone.0071495-Buchwald1], we next examined S79A mutation effect on the PAK1 interaction with the Cdc42 and Rac1 GTPases. To this end, GFP-PAK1 and GFP-PAK1^S79A^ were coexpressed with Cdc42 or Rac1 in 293T cells, and their interaction was assessed by Co-IP/Western blot analysis. Wild type PAK1 was shown to interact with Cdc42 ([Fig. 2A](#pone-0071495-g002){ref-type="fig"}) and Rac1 ([Fig. 2B](#pone-0071495-g002){ref-type="fig"}). However, the ability of PAK1^S79A^ to interact with the GTPases was markedly decreased; the binding affinity of PAK1^S79A^ for Cdc42 was reduced by ∼3-fold ([Fig. 2A](#pone-0071495-g002){ref-type="fig"}), whereas the Pak1 interaction with Rac1 was barely detectable ([Fig. 2B](#pone-0071495-g002){ref-type="fig"}). GST pull-down analysis also revealed a direct interaction between GFP-PAK1 (WT) and GST-Cdc42 (C) or GST-Rac1 (D) bound to GST-beads, whereas PAK1^S79A^ mutant has reduced affinity for both GTPases, for Rac1 in particular. However, we also found that S79D mutation does not affect in PAK1 activity towards MBP ([Fig. 2E](#pone-0071495-g002){ref-type="fig"}) and in the PAK1 interaction with Rac1 ([Fig. 2F](#pone-0071495-g002){ref-type="fig"}).

![S79A mutation impairs the interaction of PAK1 with Cdc42 and Rac1.\
(**A**) Interaction between Myc-Cdc42 and GFP-PAK1. GFP-PAK1^WT^ or GFP-PAK1^S79A^ was coexpressed with Myc-Cdc42 in 293T cells. Cell extracts were immunoprecipitated with anti-GFP antibody (IP) and then immunoblotted with anti-GFP or anti-Myc antibody (left). (**B**) Interaction between GFP-Rac1 and Myc-PAK1. Cell extracts were immunoprecipitated with anti-Myc antibody (IP) and then immunoblotted with anti-Myc or anti-GFP antibody. (**C and D**) Cell lysates prepared from 293T cells expressing GFP- PAK1^WT^ or GFP- PAK1^S79A^ were incubated with GST-Cdc42 (C) or GST-Rac1 (D) bound to GST-beads. Upper panels, Western blot analysis of the eluates from the beads using anti-GFP antibody; Lower panels, the blots were stained with Ponceau S Stain. MW markers; molecular weight markers.](pone.0071495.g002){#pone-0071495-g002}

The S79A Mutation Impairs the Ability of PAK1 to Induce Changes in Cell Morphology and Motility {#s2c}
-----------------------------------------------------------------------------------------------

PAK1 is translocated to the focal adhesions and membrane ruffles [@pone.0071495-Ahmed1], [@pone.0071495-Sells1] and the sites of cortical actin remodeling [@pone.0071495-Deshiere1] in stimulated cells. We examined the functional importance of PAK1^S79^ by comparing the morphology and motility of PAK1^−/−^ MEF (mouse embryonic fibroblast) cells expressing GFP-PAK1 and GFP-PAK1^S79A^ ([Fig. 3A](#pone-0071495-g003){ref-type="fig"}). Wild type MEF cells (PAK1^+/+^) exhibited a bipolar fusiform shape ([Fig. 3A](#pone-0071495-g003){ref-type="fig"}, a--c), whereas PAK1^−/−^ MEF cells displayed a more rounded morphology ([Fig. 3A](#pone-0071495-g003){ref-type="fig"}, d--f). Expression of GFP-PAK1 in PAK1^−/−^ MEF cells restored the wild type cell shape ([Fig. 3A](#pone-0071495-g003){ref-type="fig"}, g--i), whereas GFP-PAK1^S79A^ expression did not rescue this defect ([Fig. 3A](#pone-0071495-g003){ref-type="fig"}, j--l). F-actin was colocalized with PAK1, as observed previously in Swiss 3T3 cells [@pone.0071495-Sells1]; however, this colocalization was significantly reduced in MEF cells expressing PAK1^S79A^ ([Fig. 3A](#pone-0071495-g003){ref-type="fig"} and [Fig. S1](#pone.0071495.s001){ref-type="supplementary-material"}). MEF cells expressing GFP-PAK1^S79A^ exhibited 1.5∼2 fold decrease in the ratio of length to width (L/W), compared with MEF cells expressing GFP-PAK1, whereas those cells expressing GFP-PAK1^S79D^ displayed ∼1.5 fold decrease in the ratio of L to W ([Fig. 3B](#pone-0071495-g003){ref-type="fig"}). Wound healing migration assays showed that impaired ability of PAK1^−/−^ MEF cells to migrate into, and close to, the wound was restored by expression of GFP-PAK1 but not of GFP-PAK1^S79A^ ([Fig. 3C](#pone-0071495-g003){ref-type="fig"}).

![The S79A mutation impairs the ability of PAK1 to regulate cell morphology and motility.\
(**A**) Wild type (a--c) and PAK1^−/−^ (d--f) MEF cells were stained with the high affinity F-actin probe Phalloidin (red) and DAPI (blue). PAK1^−/−^ MEF cells expressing GFP-PAK1^WT^ (WT, g--i) and GFP-PAK1^S79A^ (S79A, j--l) were stained with Phalloidin (red) and DAPI (blue) and visualized by GFP fluorescence (green). (**B**) Quantification of the length and width (L/W) ratio of MEF cells was obtained as described previously [@pone.0071495-Sidani1]. (**C**) Wound healing migration assays of PAK1^−/−^ MEF cells infected with lentivirus expressing the vector control, GFP- PAK1^WT^, or GFP-PAK1^S79A^. Results were expressed as the percentage of the remaining area determined by normalizing the area of wound after 24 h to the initial wound area at 0 h (set to 100%). Each bar represents the mean ± S.D of five fields measured.](pone.0071495.g003){#pone-0071495-g003}

Next, we compared the ability of wild type and mutant (S79A) PAK1 proteins to confer a migration phenotype on the benign prostate RWPE-1 cells. To this end, RWPE-1 cells were infected with lentivirus expressing the vector plasmid, GFP-PAK1, or GFP-PAK1^S79A^ (S79A). Western blot analysis indicated no significant difference in the expression of GFP-PAK1 and GFP-PAK1^S79A^ in RWPE-1 cells ([Fig. 4A](#pone-0071495-g004){ref-type="fig"} ^a)^). Cell invasion assay showed that expression of GFP-PAK1, but not of GFP-PAK1^S79A^, confers an invasive phenotype to RWPE-1 cells ([Fig. 4A](#pone-0071495-g004){ref-type="fig"}). We also examined cell morphology of RWPE-1 cells expressing PAK1 or PAK1^S79A^. The formation of membrane ruffles was increased by ∼2.5-fold ([Fig. 4C](#pone-0071495-g004){ref-type="fig"}) in RWPE-1 cells expressing GFP-PAK1 ([Fig. 4B](#pone-0071495-g004){ref-type="fig"}, d--f), compared with cells expressing GFP-PAK1^S79A^ ([Fig. 4B](#pone-0071495-g004){ref-type="fig"}, g--i) or control cells ([Fig. 4B](#pone-0071495-g004){ref-type="fig"}, a--c). These results are consistent with previous observations that PAK1 regulates the formation of membrane ruffles of Swiss 3T3 cells [@pone.0071495-Sells1] and breast cancer cells [@pone.0071495-Adam1]. We also found that RWPE-1 cells fill ∼30% and ∼60% of the wounded areas by expression of PAK1 and PAK1^S79A^, respectively, at 24 h after scratching ([Fig. 4D](#pone-0071495-g004){ref-type="fig"} and [Fig. 4E](#pone-0071495-g004){ref-type="fig"}). These observations demonstrate that S79 is crucial for PAK1-mediated cell migration.

![S79A mutation abolishes the migration activity of PAK1.\
The benign prostate RWPE-1 cells infected with lentivirus expressing the vector plasmid, GFP- PAK1^WT^ (WT), or GFP-PAK1^S79A^ (S79A) were used for experiments (A) to (E). (**A**) The invasion rate was determined by counting the cells that migrated through BME-coated inserts in the Transwell Boyden chamber and expressed as the percentage relative to control (vector). Each bar represents the mean ± S.D of five fields counted. ^a)^ Western blot analysis of PAK1 expression using anti-GFP antibody. Actin was used as an internal control. (**B**) The S79A mutation impairs the ability of PAK1 to regulate formation of membrane ruffles of cells. RWPE-1 cells infected with lentivirus expressing the vector plasmid (a--c), GFP-PAK1^WT^ (WT, d--f) or GFP-PAK1^S79A^ (S79A, g--i) were stained with Phalloidin (red) and DAPI (blue) and visualized by GFP fluorescence (green). (**C**) Quantification of the cells with membrane ruffles (B). (**D**) Wound healing migration assays of RWPE-1 cells expressing GFP-PAK1 or GFP-PAK1^S79A^. (**E**) Each bar represents the mean ± S.D of five fields measured in (**D**).](pone.0071495.g004){#pone-0071495-g004}

A PAK1-inhibiting Peptide (TAT-PAK1~67--84~) Blocks the Growth of the Prostate Cancer Cell Line PC3 {#s2d}
---------------------------------------------------------------------------------------------------

Given that PAK1 activation is triggered by interaction with Cdc42 and Rac1, we examined whether PAK1 activity is reduced by a PAK1-inhibiting peptide. Towards this aim, a peptide containing the CRIB (PAK1~67--84~) was chemically synthesized ([Fig. 5A](#pone-0071495-g005){ref-type="fig"}) and fused to the C-terminus of the TAT protein polybasic sequence to facilitate entry into cells as a protein transduction domain [@pone.0071495-Ho1], [@pone.0071495-Yang1]. PC3 cells were treated with the peptide at low (2 µg/ml) and high (20 µg/ml) concentrations and were examined for cell growth by MTT assay. We found that treatment of the PAK1 peptide has ∼2-fold inhibitory effect at high dose used ([Fig. 5B](#pone-0071495-g005){ref-type="fig"}). To confirm the significance of S79 in the activation process of PAK1 as described above, we also generated a TAT-PAK1~67--84~ peptide with S79A mutation and tested its ability to inhibit PAK1 activation. Western blot analysis indicated that S144 phosphorylation is reduced by ∼40% by the treatment of the PAK1 peptide but is not affected by the treatment of the PAK1 (S79A) peptide ([Fig. 5C](#pone-0071495-g005){ref-type="fig"}). We also examined the inhibitory effect of the PAK1-inhibiting peptide on the morphology PAK1^+/+^ MEF cells ([Fig. 5D](#pone-0071495-g005){ref-type="fig"}). The bipolar fusiform shape of MEF cells (PAK1^+/+^) was changed to a more rounded morphology by treatment of the PAK1-inhibiting peptide, whereas the treatment of the PAK1 (S79A) peptide has little effect on the morphology of MEF cells ([Fig. S2](#pone.0071495.s002){ref-type="supplementary-material"}).

![A PAK1-inhibiting peptide blocks the growth of the prostate cancer cell PC3.\
(**A**) Schematic design of a PAK1-inhibiting peptide (TAT-PAK1 peptide; PAK peptide, aa 67--84). The CRIB domain is underlined. (**B**) PC3 cells were treated with 2 µg/ml or 20 µg/ml of each peptide and examined by MTT assay for 4 days. Cell viability over time was expressed as fold increase, compared with the initial absorbance at day 0. Error bars represent mean ± S.D (n = 5). (**C**) Western blot analysis of S144 phosphorylation of PAK1 in PC3 cells treated with TAT peptide, TAT-PAK1 peptide (WT) or TAT-PAK1 (S79A). (**D**) MEF cells were stained with the high affinity F-actin probe Phalloidin (red) and DAPI (blue) after treatment with with TAT peptide, TAT-PAK1 peptide (WT) or TAT-PAK1 (S79A) (left). Quantification of the length and width (L/W) ratio of MEF cells was obtained as described previously (right). (**E**) A structural overview of CRIP domain of PAK1 (red, 75--83 a.a) with bound Cdc42 (blue, 40--46 a.a). Data Bank ID number 1E0A and visualized using Molsoft ICM Browser (Molsoft, L.L.C., San Diego, CA, USA).](pone.0071495.g005){#pone-0071495-g005}

Conclusion {#s2e}
----------

The CRIB proteins such as PAK1-3 kinases [@pone.0071495-Sells1], ACK tyrosine kinases [@pone.0071495-Leesmidt1], [@pone.0071495-Hegde1] and the Wiscott-Aldrich-syndrom proteins (WASPs) [@pone.0071495-Grannell1], [@pone.0071495-Lin1] are activated by direct binding to Cdc42 [@pone.0071495-Hoffman1]. While PAK binds to both Cdc42 and Rac, ACK and WASP do not bind to Rac [@pone.0071495-Morreale1]. Structural analyses indicate that the CRIB motif of all the three proteins make an intermolecularβ-sheet interaction with the β2 strand of Cdc42 [@pone.0071495-Morreale1], [@pone.0071495-Chongtham1], [@pone.0071495-Yeo1]. Thus, mutations of the amino acid residues that are evolutionarily conserved from human to Drosophila such as I75, S76 and P78 (for sequence alignment, see [Fig. 1B](#pone-0071495-g001){ref-type="fig"}) dramatically reduces the binding affinity of PAK for Cdc42 [@pone.0071495-Zhao1]. S79 is conserved only in higher eukaryotes and one of three residues (~79~SDF~81~) forming a β-bulge that disrupts this interaction [@pone.0071495-Morreale1]. The structure of the Cdc42-PAK complex infers that S79 might interact with the V42 of Cdc42 [@pone.0071495-Morreale1] ([Fig. 5E](#pone-0071495-g005){ref-type="fig"}), whose mutation does not significantly affect the interaction of Cdc42 with PAK [@pone.0071495-Yeo1]. Hence, S79 is not essential for the PAK interaction with Cdc42. This may be in line with our finding that S79A mutation has little effect on the PAK1-Cdc42 interaction ([Fig. 2A--F](#pone-0071495-g002){ref-type="fig"}ig. 2D). However, this mutation is shown to abolish the binding of PAK1 to Rac1, suggesting that PAK1 may bind to Cdc42 and Rac1 by different mechanisms and that S79 may play a key role in enabling PAK1 to distinguish Cdc42 and Rac1. This view is reinforced by the previous work that PAKs bind Rac1 with higher affinity than Cdc42. [@pone.0071495-Chong2]. The crystal structure of the PAK1-Rac1 complex will help to elucidate the role of S79 in the interaction with and activation by Rac1.

Materials and Methods {#s3}
=====================

Reagents and Antibodies {#s3a}
-----------------------

Anti-Pak1, Pak1-pT423, Pak1-pS119 and Pak1-pS144 antibodies were from Cell Signaling. Normal mouse *Protein A/G* PLUS-*Agarose beads*, IgG, anti-actin, anti-c-Myc, and anti-GFP antibodies were from Santa Cruz Biotechnology. Recombinant EGF was from Millipore. Alexa Fluor 568 conjugated-phalloidin was from Invitrogen.

Cell Culture {#s3b}
------------

The RWPE-1 cells were grown in keratinocyte serum-free medium (K-SFM) containing bovine pituitary extract and epidermal growth factor, as described previously [@pone.0071495-Shin1]. MEF, PC3, and 293T cells were cultured in RPMI 1640 or DMEM containing 10% FBS and penicillin/streptomycin at 37°C in a humidified atmosphere of 5% CO~2~. PAK1 wild type and PAK1^−/−^ murine embryonic fibroblasts (MEFs) were kindly provided by Dr. Rakesh Kumar [@pone.0071495-SanchezSolana1]. MEFs were isolated from day 13.5 wild-type or Pak1^−/−^ embryos. Wild-type and Pak1^−/−^ MEFs were immortalized with SV40 T antigen and were maintained in DME supplemented with 12% FBS. RWPE-1, PC3, and 293T cells cell lines used in this study were obtained from the American Type Culture Collection (ATCC; Rockville, MD).

Lentiviral Infection {#s3c}
--------------------

Lentiviral expression vectors for wild-type GFP-PAK1^WT^ and mutant GFP-PAK1^S79A^ were constructed by subcloning corresponding cDNAs into pLV-puro lentiviral vector, as described previously [@pone.0071495-Shin1]. For viral production, 293T cells were co-transfected with pLV-GFP, pLV- GFP-PAK1^WT^, or pLV- GFP-PAK1^S79A^, and packaging plasmids (psPAX2 and pCMV-VSV-G) using CalPhos Mammalian Transfection Kit (Clontech).

Co-immunoprecipitation (IP) and Western Blot Analysis {#s3d}
-----------------------------------------------------

Cells expressing Pak1, Cdc42, or Rac1 were lysed in lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X100) containing phosphatase inhibitors (10 mM Na-pyrophosphate, 200 µM Na-orthovanadate, 50 mM Na-flouride). The cell lysates were incubated with appropriate antibodies overnight at 4°C. The bound proteins were eluted by boiling the beads in sodium dodecyl sulfate (SDS) sample buffer for 5 min and were resolved in SDS-polyacrylamide gels. Western blot analysis was performed, as described previously [@pone.0071495-Shin1].

Cell Invasion and Migration Assays {#s3e}
----------------------------------

Cell invasion assay was performed using the cell invasion kit (Transwell Boyden's chamber with Transwell® Permeable Support Inserts Coated with Cultrex® BME (basement membrane extract) Corning Costar) according to the manufacture's instruction. For the cell migration assay, confluent RWPE-1 or MEF cells were scratched with a P-200 pipette tip to cause wounding and subjected to the wound healing assay as described previously [@pone.0071495-Shin1].

MTT Cell Proliferation Assays {#s3f}
-----------------------------

For MTT cell proliferation assay, PC3 cells were cultured in 96-well microplate. Cell growth was evaluated by replacing the culture media with 200 µl of 0.5 mg/ml MTT-media solution after incubation for 1--4 days. The absorbance was determined at 595 nm using a microplate reader (Bio-Rad Laboratories, iMark).

In all experiments, statistical significance was defined by P-values: *\*P\<0.05, \*\*p\<0.005, \*\*\*p\<0.001* (as compared with control).

Supporting Information {#s4}
======================

###### 

**PAK1 S79A mutation impairs the ability of Pak1 to change cell morphology.** PAK1^−/−^ MEF cells expressing GFP-PAK1^WT^ (WT) and GFP-PAK1^S79A^ (S79A) were stained with Phalloidin (red) and DAPI (blue) or visualized by GFP fluorescence (green).

(TIF)

###### 

Click here for additional data file.

###### 

MEF cells were stained with the high affinity F-actin probe Phalloidin (red) after treatment with TAT (a--f) or TAT-PAK1 peptide (g--l) [@pone.0071495-SanchezSolana1].

(TIF)

###### 

Click here for additional data file.
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